Table 5 Overall survival for the entire cohort stratified by duration of follow-up

Duodenal invasion

 Yes

13

3.85 (2.7–4.9)

0.15

11

9.45 (8.3–10.6)

0.95

17

18.05 (16.2–19.9)

0.008*

12

69.58 (49.5–89.7)

0.06

 No

16

2.88 (2.0–3.7)

5

9.4 (6.8–11.9)

13

14.85 (13.7–16.0)

10

45.6 (28.1–63)

Age

 ≤ 60

7

4.43 (3.0–5.8)

0.05*

2

9 (3.7–21.7)

0.71

9

16.11 (13.7–18.5)

0.57

8

74.63 (43.7–105.5)

0.06

 > 60

22

2.95 (2.2–3.7)

14

9.5 (8.4–10.6)

21

16.90 (15.3–18.6)

14

49.57 (36.4–62.7)

Lymphovascular invasion

 Yes

21

3.38 (2.5–4.2)

0.74

14

9.8 (8.9–10.7)

0.3

20

16.4 (14.9–18.0)

0.63

15

59.3 (45.0–73.7)

0.89

 No

8

3.13 (1.8–4.5)

2

7 (7–7)

10

17.1 (14.5–19.7)

7

57.29 (19.4–95.1)

Perineural invasion

 Yes

25

3.48 (2.7–4.2)

0.20

13

9.92 (9.0–10.9)

0.01*

24

16.5 (15.2–17.9)

0.69

20

60.7 (46.2–75.2)

0.34

 No

4

2.25 (0.1–4.6)

3

7.3 (5.9–8.8)

6

17.16 (12.5–21.8)

2

38.5 (7.62–184.6)

Lymph node involved

 Yes

22

3.45 (2.6–4.3)

0.45

14

9.71 (8.7–10.7)

0.09

21

17.1 (15.4–18.8)

0.30

14

56.85 (42.2–71.3)

0.72

 No

7

2.86 (2.0–3.7)

2

7.5 (1.1–13.9)

9

15.66 (13.6–17.8)

8

61.88 (28.4–95.4)

Mortality status

 Deceased

11

2.91 (1.5–4.3)

0.35

8

9.13 (7.8–10.5)

0.49

7

16.14 (13.8–18.5)

0.65

6

39.67 (24.2–55.1)

0.07

 Alive

18

3.56 (2.8–4.3)

8

9.75 (8.2–11.3)

23

16.82 (15.2–18.4)

16

65.81 (48.7–82.9)